Richmond enrols first patients in Verve Therapeutic’s Heart-2 trial - pioneering a new approach to cardiovascular disease
June 27, 2024
Richmond enrols and doses the first patient in a clinical trial aimed at transforming the care of cardiovascular disease with single treatment gene-editing medicines.
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.